4th September 2014
Google's health company spin-off Calico announces massive investment into anti-aging research
Last year, Google announced Calico, a spin-off company with the specific aim of developing treatments for age-related diseases. In its first major step since that launch, Calico has now formed a partnership with AbbVie, another biotech firm. Together, they will collaborate to accelerate the discovery, development and commercialisation of new therapies.
The companies will co-invest up to $1.5 billion to create a world-class R&D facility in the San Francisco Bay Area. This will combine Calico's discovery and early development capabilities with AbbVie's broad research, development and commercial expertise, with a focus on aging and age-related diseases including neurodegeneration and cancer.
Art Levinson, CEO and founder of Calico, says in a press release: “Our relationship with AbbVie is a pivotal event for Calico, whose mission is to develop life-enhancing therapies for people with age-related diseases. It will greatly accelerate our efforts to understand the science of aging, advance our clinical work, and help bring important therapies to patients everywhere.”